334 related articles for article (PubMed ID: 30862149)
1. Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience.
Tunç S; Köprülü Ö; Ortaç H; Nalbantoğlu Ö; Dizdarer C; Demir K; Özkan B
Turk J Med Sci; 2019 Apr; 49(2):464-471. PubMed ID: 30862149
[TBL] [Abstract][Full Text] [Related]
2. Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution.
Ohye H; Minagawa A; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Suzuki M; Yoshihara A; Ito K; Ito K
Thyroid; 2014 Feb; 24(2):200-7. PubMed ID: 23926918
[TBL] [Abstract][Full Text] [Related]
3. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
[No Abstract] [Full Text] [Related]
4. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Antithyroid Drug Treatment of Graves' Disease in Children and Adolescents: A 20-Year Single-Center Experience.
Song A; Kim SJ; Kim MS; Kim J; Kim I; Bae GY; Seo E; Cho YS; Choi JY; Cho SY; Jin DK
Front Endocrinol (Lausanne); 2021; 12():687834. PubMed ID: 34194397
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
Chen DY; Chen TH
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
[TBL] [Abstract][Full Text] [Related]
7. The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy.
Rotondi M; Cappelli C; Pirali B; Pirola I; Magri F; Fonte R; Castellano M; Rosei EA; Chiovato L
J Clin Endocrinol Metab; 2008 Oct; 93(10):3985-8. PubMed ID: 18664537
[TBL] [Abstract][Full Text] [Related]
8. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study.
Léger J; Gelwane G; Kaguelidou F; Benmerad M; Alberti C;
J Clin Endocrinol Metab; 2012 Jan; 97(1):110-9. PubMed ID: 22031519
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort.
Jin M; Jang A; Kim CA; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Eur Thyroid J; 2023 Apr; 12(2):. PubMed ID: 36826832
[TBL] [Abstract][Full Text] [Related]
10. Graves' disease in childhood: advances in management with antithyroid drug therapy.
Kaguelidou F; Carel JC; Léger J
Horm Res; 2009; 71(6):310-7. PubMed ID: 19506387
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of hyperthyroidism diagnosed in childhood and adolescence: a single-centre experience.
Gill DS; Greening JE; Howlett TA; Levy MJ; Shenoy SD
J Pediatr Endocrinol Metab; 2019 Feb; 32(2):151-157. PubMed ID: 30685744
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of treatments for Graves disease in the children and adolescent population.
Jawwad M; Ahmed SA; Zaidi SMM; Fatmi SAA; Ashraf MH; Naeem S; Chola MS
Endocrine; 2023 Aug; 81(2):223-230. PubMed ID: 37115377
[TBL] [Abstract][Full Text] [Related]
14. Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves' Disease: A Nationwide Population-Based Cohort Study.
Song E; Kim M; Park S; Park MJ; Kim JA; Roh E; Yu JH; Kim NH; Seo JA; Kim SG; Kim NH; Choi KM; Baik SH; Yoo HJ
Front Endocrinol (Lausanne); 2021; 12():761782. PubMed ID: 34690936
[TBL] [Abstract][Full Text] [Related]
15. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
16. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
[TBL] [Abstract][Full Text] [Related]
17. [Long-term follow up after antithyroid drug treatment in Graves' disease].
Wille T; Müller B; Noth D; Bürgi U; Diem P
Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis.
Shi H; Sheng R; Hu Y; Liu X; Jiang L; Wang Z; Cui D
Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177
[TBL] [Abstract][Full Text] [Related]
19. When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?
Park S; Song E; Oh HS; Kim M; Jeon MJ; Kim WG; Kim TY; Shong YK; Kim DM; Kim WB
Endocrine; 2019 Aug; 65(2):348-356. PubMed ID: 31236779
[TBL] [Abstract][Full Text] [Related]
20. "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients.
Vigone MC; Peroni E; Di Frenna M; Mora S; Barera G; Weber G
J Endocrinol Invest; 2020 May; 43(5):595-600. PubMed ID: 31713721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
